Document Detail

Wharton's jelly or bone marrow mesenchymal stromal cells improve cardiac function following myocardial infarction for more than 32 weeks in a rat model: A Preliminary Report.
MedLine Citation:
PMID:  23270633     Owner:  NLM     Status:  Publisher    
The therapeutic effect of mesenchymal stromal cells (MSCs) following myocardial infarction (MI) is small. This may be due to differences in cellular sources and donor age, route of administration, in vitro cellular manipulations and the short time course of follow up in many animal studies. Here, we compared MSCs from two different sources (adult bone marrow or Wharton's jelly from umbilical cord) for their long-term therapeutic effect following MI in a rat model to evaluate the effect of donor age. MSCs (or control infusions) were given intravenously 24-48 hr after myocardial ischemia (MI) induced by coronary artery ligation. Cardiac function was assessed by ultrasound at time points starting from before MSC infusion through 68 weeks after MI. A significant improvement in ejection fraction was seen in animals that received MSCs in time points 25 to 31 wks after treatment (p <0.01). These results support previous work that show that MSCs can cause improvement in cardiac function and extend that work by showing that the beneficial effects are durable. To investigate MSCs' cardiac differentiation potential, Wharton's jelly MSCs were co-cultured with fetal or adult bone-derived marrow MSCs. When Wharton's jelly MSCs were co-cultured with fetal MSCs, and not with adult MSCs, myotube structures were observed in two-three days and spontaneous contractions (beating) cells were observed in five-seven days. The beating structures formed a functional syncytium indicated by coordinated contractions (beating) of independent nodes. Taken together, these results suggest that MSCs given 24-48 hr after MI have a significant and durable beneficial effect more than 25 weeks after MI and that MSC treatment can home to damaged tissue and improve heart function after intravenous infusion 24-48 hrs after MI, and that WJCs may be a useful source for off-the-shelf cellular therapy for MI.
Yelica López; Barbara Lutjemeier; Kiran Seshareddy; Elizabeth M Trevino; K Sue Hageman; Timothy I Musch; Michele Borgarelli; Mark L Weiss
Related Documents :
18672303 - Transcription factor gata-4 is involved in erythropoietin-induced cardioprotection agai...
9172383 - Protective effect of diltiazem on myocardial ischemic injury associated with .oh genera...
11917193 - The prevalence of impaired left ventricular diastolic filling is related to the extent ...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-12-24
Journal Detail:
Title:  Current stem cell research & therapy     Volume:  -     ISSN:  1574-888X     ISO Abbreviation:  Curr Stem Cell Res Ther     Publication Date:  2012 Dec 
Date Detail:
Created Date:  2012-12-28     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101272517     Medline TA:  Curr Stem Cell Res Ther     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Dept of Anatomy and Physiology, Kansas State University Coles Hall, room 105, Manhattan, KS 66506, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Myogenic potential of mesenchymal stem cells - the case of adhesive fraction of human umbilical cord...
Next Document:  Immunogenicity and Immunomodulatory Properties of Hepatocyte-like Cells Derived from Human Amniotic ...